BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31922558)

  • 1. Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis.
    Paoletti X; Lewsley LA; Daniele G; Cook A; Yanaihara N; Tinker A; Kristensen G; Ottevanger PB; Aravantinos G; Miller A; Boere IA; Fruscio R; Reyners AKL; Pujade-Lauraine E; Harkin A; Pignata S; Kagimura T; Welch S; Paul J; Karamouza E; Glasspool RM;
    JAMA Netw Open; 2020 Jan; 3(1):e1918939. PubMed ID: 31922558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis.
    Corbaux P; You B; Glasspool RM; Yanaihara N; Tinker AV; Lindemann K; Ray-Coquard IL; Mirza MR; Subtil F; Colomban O; Péron J; Karamouza E; McNeish I; Kelly C; Kagimura T; Welch S; Lewsley LA; Paoletti X; Cook A
    Eur J Cancer; 2023 Sep; 191():112966. PubMed ID: 37542936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of progression-free survival as a surrogate end point in primary CNS lymphoma: a systematic review and meta-analysis.
    Zhan J; Yang S; Zhang W; Zhou D; Zhao D; Zhang Y; Wang W; Wei C
    Future Oncol; 2023 Oct; 19(31):2123-2133. PubMed ID: 37882339
    [No Abstract]   [Full Text] [Related]  

  • 4. Validity and Efficiency of Progression-Free Survival-2 as a Surrogate End Point for Overall Survival in Advanced Cancer Randomized Trials.
    Woodford R; Zhou D; Kok PS; Lord SJ; Friedlander M; Marschner I; Simes RJ; Lee CK
    JCO Precis Oncol; 2024 Jan; 8():e2300296. PubMed ID: 38207226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis.
    Rotolo F; Pignon JP; Bourhis J; Marguet S; Leclercq J; Tong Ng W; Ma J; Chan AT; Huang PY; Zhu G; Chua DT; Chen Y; Mai HQ; Kwong DL; Soong YL; Moon J; Tung Y; Chi KH; Fountzilas G; Zhang L; Hui EP; Lee AW; Blanchard P; Michiels S;
    J Natl Cancer Inst; 2017 Apr; 109(4):. PubMed ID: 27927756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-Analysis of Candidate Surrogate End Points in Advanced Prostate Cancer.
    Gharzai LA; Jiang R; Jaworski EM; Morales Rivera K; Dess RT; Jackson WC; Hartman HE; Mehra R; Kishan AU; Solanki AA; Schaeffer EM; Feng FY; Zaorsky NG; Berlin A; Ponsky L; Shoag J; Sun Y; Schipper MJ; Garcia J; Spratt DE
    NEJM Evid; 2023 Apr; 2(4):EVIDoa2200195. PubMed ID: 38320030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials.
    Wang ZX; Wu HX; Xie L; Lin WH; Liang F; Li J; Yang ZM; Xu RH
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression-free survival is a weakly predictive surrogate end-point for overall survival in follicular lymphoma: A systematic review and meta-analysis.
    Milrod CJ; Kim KW; Raker C; Ollila TA; Olszewski AJ; Pelcovits A
    Br J Haematol; 2024 Jun; 204(6):2237-2241. PubMed ID: 38571449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma.
    Dimopoulos M; Sonneveld P; Manier S; Lam A; Roccia T; Schecter JM; Cost P; Pacaud L; Poirier A; Tremblay G; Lan T; Valluri S; Kumar S
    BMC Cancer; 2024 Apr; 24(1):541. PubMed ID: 38684948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer.
    Roncolato F; King MT; O'Connell RL; Lee YC; Joly F; Hilpert F; Lanceley A; Yoshida Y; Bryce J; Donnellan P; Oza A; Avall-Lundqvist E; Berek JS; Ledermann JA; Berton D; Sehouli J; Kaminsky MC; Stockler MR; Friedlander M
    Gynecol Oncol; 2024 Jun; 185():128-137. PubMed ID: 38412736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is overall survival still the primary endpoint in maintenance non-small cell lung cancer studies? An analysis of phase III randomised trials.
    Petrelli F; Barni S
    Transl Lung Cancer Res; 2013 Feb; 2(1):6-13. PubMed ID: 25806200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations Between Surrogate Markers and Clinical Outcomes for Nononcologic Chronic Disease Treatments.
    Wallach JD; Yoon S; Doernberg H; Glick LR; Ciani O; Taylor RS; Mooghali M; Ramachandran R; Ross JS
    JAMA; 2024 May; 331(19):1646-1654. PubMed ID: 38648042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surrogate endpoints in phase III randomized trials of advanced gastroesophageal cancer: A systematic review and meta-analysis.
    Rodríguez JV; Prieto A; Terre EV; Bonet M; Diez M; Salud A; Montal R
    Crit Rev Oncol Hematol; 2024 Jun; ():104416. PubMed ID: 38871262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective.
    Oza AM; Castonguay V; Tsoref D; Diaz-Padilla I; Karakasis K; Mackay H; Welch S; Weberpals J; Hoskins P; Plante M; Provencher D; Tonkin K; Covens A; Ghatage P; Gregoire J; Hirte H; Miller D; Rosen B; Maroun J; Buyse M; Coens C; Brady MF; Stuart GC
    Curr Oncol; 2011 Oct; 18 Suppl 2(Suppl 2):S20-7. PubMed ID: 21969808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella and Mammella Intergruppo trials.
    Blondeaux E; Xie W; Carmisciano L; Mura S; Sanna V; De Laurentiis M; Caputo R; Turletti A; Durando A; De Placido S; De Angelis C; Bisagni G; Gasparini E; Rimanti A; Puglisi F; Mansutti M; Landucci E; Fabi A; Arecco L; Perachino M; Bruzzone M; Boni L; Lambertini M; Del Mastro L; Regan MM
    EClinicalMedicine; 2024 Apr; 70():102501. PubMed ID: 38685923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surrogate endpoints for overall survival in randomised controlled trials of localised osteosarcoma: A meta-analytic evaluation.
    Tanaka K; Kawano M; Iwasaki T; Matsuda S; Itonaga I; Tsumura H
    Sci Rep; 2020 May; 10(1):8573. PubMed ID: 32444660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dexamethasone and overall survival and progression free survival in patients with newly diagnosed glioblastoma: a meta-analysis.
    Arora H; Mammi M; Patel NM; Zyfi D; Dasari HR; Yunusa I; Simjian T; Smith TR; Mekary RA
    J Neurooncol; 2024 Jan; 166(1):17-26. PubMed ID: 38151699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of the Randomized Clinical Trial in the Era of Precision Oncology.
    Del Paggio JC; Berry JS; Hopman WM; Eisenhauer EA; Prasad V; Gyawali B; Booth CM
    JAMA Oncol; 2021 May; 7(5):728-734. PubMed ID: 33764385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lessons learned from contemporary glioblastoma randomized clinical trials through systematic review and network meta-analysis: part 2 recurrent glioblastoma.
    Taslimi S; Ye VC; Wen PY; Zadeh G
    Neurooncol Adv; 2021; 3(1):vdab029. PubMed ID: 34042101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Benefits and Risks of Receiving Investigational Solid Tumor Drugs in Randomized Trials : A Systematic Review and Meta-analysis.
    Iskander R; Moyer H; Fergusson D; McGrath S; Benedetti A; Kimmelman J
    Ann Intern Med; 2024 Apr; ():. PubMed ID: 38684102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.